DOTA-Zoledronate is a next generation agent for bone Targeted Radionuclide Therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for PET-Imaging and radionuclide therapy.
This novel bisphosphonate derivative is attractive for tagging of beta-emitting n.c.a. Lutetium-177 (EndolucinBeta®) as well as the generator derived PET-radionuclide Gallium-68. Due to its versatile properties for radiolabeling, DOTA-Zoledronate is also a promising precursor for the development of other future-oriented radionuclide therapeutic concepts in the field of Precision Oncology, such as targeted alpha particle therapy.